Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

The document describes a case where a 17-year-old patient with Alopecia Areata (AA) and CANDLE syndrome experienced complete hair regrowth after treatment with the JAK1/2 inhibitor baricitinib. Initially suffering from chronic patch-type AA for seven years, the patient saw remarkable improvement within three months of starting treatment, and after nine months, achieved full resolution of hair loss. Complementary in vivo experiments with the C3H/HeJ AA mouse model demonstrated a correlation between the resolution of the interferon signature and clinical improvement. These results indicate that baricitinib could be an effective treatment for AA, and further clinical trials are warranted. The document also notes that JAK inhibitors like baricitinib are advantageous due to their oral bioavailability and ability to target multiple pathways, suggesting their potential utility in AA treatment. The study primarily revolves around a single patient case and animal model research.